Doxycycline Plus Streptomycin Versus Ciprofloxacin Plus Rifampicin in Spinal Brucellosis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN31053647

Enrollment

Registered

2006-03-29

Start date

2002-01-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brucellosis is an infectious disease affecting multiple systems including vertebrae Infections and Infestations Spinal brucellosis

Interventions

To compare the efficacy, adverse drug reactions, complications and cost of ciprofloxacin plus rifampicin versus doxycycline plus streptomycin in the treatment of spinal brucellosis

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients diagnosed with spinal brucellosis between January 2002 to December 2004 were enrolled into two study groups consecutively

Exclusion criteria

Exclusion criteria: 1. Age less than 16 years 2. Pregnancy 3. Neurobrucellosis 4. Previous history of brucellosis and antimicrobial therapy and discontinuation of the therapy for any reason (allergy to any of the drugs, death, adverse reactions)

Design outcomes

Primary

Measure	Time frame
1. Clinical efficacy of ciprofloxacin plus rifampicin in spinal brucellosis 2. The prevalence of relapses	—

Secondary

Measure	Time frame
The cost of the two regimens	—

Countries

Turkey

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026